Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
Nurix Therapeutics (Nasdaq: NRIX) announces participation in the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Key sessions include:
- Pre-Conference Workshop on TPD basics by Gwenn M. Hansen, Ph.D. on October 26 at 8:30 a.m. ET.
- Oral Session on clinical updates by CEO Arthur T. Sands, M.D., Ph.D. on October 27 at 11:45 a.m. ET.
- Panel Discussions on therapeutic applications and diversity led by Sands and Hansen on October 27 and 28.
This summit highlights Nurix's commitment to advancing targeted protein modulation for cancer treatment.
- None.
- None.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.
Details of Nurix’s presentations:
Tuesday, October 26
Pre-Conference Workshop: TPD 101: Invigorate Your Knowledge of Targeted Protein Degradation
Gwenn M. Hansen, Ph.D., CSO, Nurix
8:30 a.m. ET
Wednesday, October 27
Oral Session: Clinical Update on Degraders in the Clinic, Key Learnings & Future Directions
Turning Degraders into Drugs – NX-2127 & NX-5948
Arthur T. Sands, M.D., Ph.D., President and CEO
11:45 a.m. ET
Panel Discussion: The Next Wave of Therapeutics: Applications of Protein Degradation for Oncology & Beyond
Arthur T. Sands, M.D., Ph.D.
12:15 p.m. ET
Thursday, October 28
Panel Discussion: Expanding Diversity & Inclusion in Targeted Protein Degradation Field
Gwenn M. Hansen, Ph.D.
9:30 a.m. ET
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com/.
Forward Looking Statement
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of our clinical trial programs for our drug candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase™ platform and drug candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the estimated size of the market for our drug candidates; and the timing and success of the development and commercialization of our anticipated drug candidates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, future plans and strategies, its development plans, its preclinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix’s ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of preclinical and clinical trials; (iii) Nurix’s ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (v) Nurix’s ability to protect intellectual property and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 16, 2021, Nurix’s Quarterly Report on Form 10-Q filed with the SEC on October 14, 2021, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.
| Contacts: | |
| Investors: | Media: |
| Jason Kantor, Ph.D. | Elizabeth Wolffe, Ph.D. |
| Nurix Therapeutics, Inc. | Wheelhouse Life Science Advisors |
| jkantor@nurixtx.com | lwolffe@wheelhouselsa.com |
FAQ
What is the date of the 4th Annual Targeted Protein Degradation Summit for Nurix?
Who from Nurix will present at the TPD Summit?
What key topics will be discussed at the summit by Nurix?
What time is Gwenn M. Hansen's workshop at the TPD Summit?
When is Arthur T. Sands' oral session during the TPD Summit?
